Views & Analysis Orphan drugs will fuel pharma's future - and a pricing pushb... Evaluate predicts sales could approach $8bn if approved.
News Teva files orphan blockbuster hope in tardive dyskinesia SD-809 will be vital for Teva if approved.
News Pharma must slash rare disease drug prices - patient organis... More rare disease drugs must also be approved, says EURORDIS.
News NICE rejects second Alexion ultra-rare disease drug NHS will not fund Kanuma for rare disease LAL-D.
News Marathon halts launch of Duchenne drug after price outcry Company says it will listen to concerns of patient advocates
News Alexion lambasts NICE over rare disease ruling Watchdog accused of ignoring stakeholder consensus and call for negotiations
News UK's Mission divests kidney drug to Dimerix for $292m Mission Therapeutics has struck a deal to out-license a drug for acute kidney injury to Australia's Dimerix, sharpening its focus on CNS diseases.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
